LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
- Your personalised programme is built around medical care, not willpower.
- No generic diets. No guesswork.
- Just science-backed results and expert support.
Find out if you’re eligible
Weight loss injections like semaglutide (Wegovy) and tirzepatide (Zepbound) have transformed obesity management, but many patients wonder about their impact on energy levels. Fatigue is a documented side effect in FDA prescribing information, reported in 11.4% of Wegovy users and 7.2-10.8% of Zepbound users during clinical trials. This tiredness may stem from the medication itself, significant caloric reduction, metabolic adaptation, or nutritional factors. Understanding why fatigue occurs and how to manage it effectively helps patients continue treatment safely while maintaining quality of life. This guide examines the connection between weight loss injections and tiredness, offering evidence-based strategies for managing this common concern.
Quick Answer: Weight loss injections can cause fatigue, with clinical trials showing tiredness in 11.4% of semaglutide users and 7.2-10.8% of tirzepatide users compared to lower rates in placebo groups.
Weight loss injections have become increasingly popular for managing obesity and type 2 diabetes. These medications include glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Wegovy) and liraglutide (Saxenda), as well as the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide (Zepbound).
These medications work by mimicking natural hormones that regulate appetite and blood sugar levels, leading to reduced food intake and subsequent weight loss. They slow gastric emptying, enhance insulin secretion when blood glucose is elevated, and reduce glucagon release. These medications also act on brain receptors that control appetite, creating feelings of fullness and reducing hunger signals.
The FDA has approved specific injectable medications for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide), and Saxenda (liraglutide 3 mg) are FDA-approved for weight management, while Ozempic (semaglutide) and Mounjaro (tirzepatide) are approved for type 2 diabetes management.
These injections can be highly effective for weight loss—with clinical trials showing average weight reductions of approximately 15% for semaglutide and up to 20-22% for tirzepatide. However, they are associated with various side effects. The most commonly reported adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation. Patients and healthcare providers have also noted other systemic effects, including changes in energy levels and fatigue.
Importantly, these medications carry boxed warnings about the risk of thyroid C-cell tumors and are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Understanding the full spectrum of potential effects is essential for patients considering or currently using these medications. This knowledge enables informed decision-making and helps distinguish between expected medication effects, consequences of rapid weight loss, and symptoms requiring medical attention.
LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
Find out if you’re eligible
Fatigue is a recognized adverse reaction listed in the FDA prescribing information for weight loss injections. For Wegovy (semaglutide 2.4 mg), fatigue was reported in 11.4% of patients compared to 5.2% in the placebo group during clinical trials. Similarly, for Zepbound (tirzepatide), fatigue was reported in 7.2-10.8% of patients (depending on dose) versus 4.1% in the placebo group.
The relationship between weight loss injections and fatigue is complex. In the pivotal STEP trials for semaglutide and SURMOUNT trials for tirzepatide, fatigue was systematically tracked and occurred more frequently in treatment groups than placebo groups. Clinical experience suggests that some patients experience notable tiredness, particularly during the initial weeks of treatment or after dose escalations. The incidence appears variable, with some individuals reporting no energy changes while others describe significant fatigue that impacts daily functioning.
It is important to distinguish between direct medication effects and indirect consequences of the physiological changes these drugs induce. The tiredness many patients experience may result from multiple factors related to the medication's intended effects as well as the pharmacological properties of these agents.
Fatigue risk may be higher during dose titration periods. Most of these medications require gradual dose increases over several weeks to months to minimize side effects, including fatigue. For example, Wegovy starts at 0.25 mg weekly and increases monthly until reaching the maintenance dose of 2.4 mg weekly.
Healthcare providers should acknowledge patient reports of fatigue seriously, as it is a documented side effect. A thorough evaluation can help determine whether tiredness represents a medication side effect, a consequence of dietary changes, an underlying medical condition, or a combination of factors requiring individualized management strategies.
Several mechanisms may explain why patients experience fatigue while using weight loss injections. Understanding these potential causes helps guide appropriate management and reassures patients that their symptoms have identifiable explanations.
Caloric Deficit and Nutritional Factors
The primary mechanism of weight loss with these medications is appetite suppression, which leads to significantly reduced caloric intake. This substantial caloric deficit, while necessary for weight loss, can result in decreased energy availability for daily activities. Additionally, some patients may inadvertently develop nutritional deficiencies if their reduced food intake lacks adequate protein, vitamins, or minerals, particularly B vitamins and iron, which are essential for energy metabolism.
Metabolic Adaptation
Weight loss triggers metabolic adaptations as the body adjusts to a lower energy state. Basal metabolic rate may decrease, and hormonal changes occur that can affect energy levels. The body may temporarily reduce non-essential energy expenditure, manifesting as fatigue, as it adapts to the new metabolic environment.
Gastrointestinal Side Effects
Nausea, vomiting, and other gastrointestinal symptoms—the most common side effects of these medications—can indirectly cause fatigue. Persistent nausea may further reduce food intake beyond the medication's appetite-suppressing effects, and gastrointestinal distress can disrupt sleep quality, leading to daytime tiredness.
Blood Sugar Effects
These medications help stabilize blood glucose, but some patients, particularly those with diabetes or prediabetes, may experience changes in glucose levels as their medication regimen adjusts. When used as monotherapy, GLP-1 receptor agonists and GIP/GLP-1 receptor agonists have a low risk of hypoglycemia. However, when combined with insulin or sulfonylureas, the risk increases significantly and may contribute to fatigue.
Dehydration
Reduced appetite may also decrease fluid intake, and gastrointestinal side effects can lead to fluid losses. Even mild dehydration can cause significant fatigue, headaches, and difficulty concentrating.
Gallbladder Disease
Weight loss medications carry a risk of gallbladder problems, including gallstones. This is a labeled risk that can present with right upper quadrant pain, nausea, and systemic symptoms including fatigue.
If you experience tiredness while using weight loss injections, several evidence-based strategies can help manage this symptom while continuing your treatment safely and effectively.
Optimize Nutritional Intake
Despite reduced appetite, prioritize nutrient-dense foods that provide essential vitamins, minerals, and macronutrients. Focus on adequate protein intake (1.2-1.6 grams per kilogram of body weight daily, if appropriate and if kidney function is normal) to preserve lean muscle mass during weight loss. Include iron-rich foods such as lean meats, beans, and fortified cereals, and ensure sufficient B-vitamin intake through whole grains, eggs, and leafy greens. Discuss with your healthcare provider whether a multivitamin supplement would be appropriate for your individual situation, particularly if your food intake is significantly restricted.
Maintain Adequate Hydration
Stay well-hydrated throughout the day, adjusting for activity level, climate, and individual needs. Monitor your hydration status through thirst signals and urine color (pale yellow indicates good hydration). Set reminders if reduced thirst accompanies your decreased appetite. Adequate hydration supports all metabolic processes and can significantly improve energy levels.
Gradual Dose Titration
Work with your healthcare provider to ensure appropriate dose escalation. Most GLP-1 receptor agonists and GIP/GLP-1 receptor agonists require gradual titration over several weeks to months. If fatigue is severe with dose increases, your provider may recommend staying at a lower dose longer before advancing, allowing your body more time to adapt.
Monitor Physical Activity
While regular exercise is important for overall health and weight maintenance, you may need to temporarily modify intensity or duration if experiencing significant fatigue. Focus on moderate activities like walking rather than high-intensity workouts during adjustment periods. Gradually increase activity as energy levels improve.
Prioritize Sleep Quality
Ensure 7-9 hours of quality sleep nightly. Establish consistent sleep schedules and create an environment conducive to rest. Address any sleep disturbances promptly, as poor sleep compounds medication-related fatigue.
Consider Professional Nutrition Guidance
A registered dietitian can provide personalized nutrition planning to ensure you're meeting nutritional needs while using weight loss medications. They can help develop strategies to maximize nutrient intake despite reduced appetite and address specific deficiencies that might contribute to fatigue.
While mild fatigue may be manageable with lifestyle modifications, certain situations warrant prompt medical evaluation to rule out complications or underlying conditions requiring intervention.
Severe or Worsening Fatigue
Contact your healthcare provider if tiredness is severe enough to interfere with daily activities, work, or self-care, or if fatigue progressively worsens rather than improving as your body adjusts to the medication. Debilitating exhaustion is not an expected or acceptable side effect and requires thorough evaluation.
Symptoms Suggesting Hypoglycemia
Seek immediate medical attention if fatigue is accompanied by shakiness, sweating, confusion, rapid heartbeat, dizziness, or extreme hunger. These symptoms may indicate low blood sugar, particularly if you take other diabetes medications alongside GLP-1 receptor agonists or GIP/GLP-1 receptor agonists. Patients using insulin or sulfonylureas face higher hypoglycemia risk and may require medication adjustments.
Signs of Dehydration or Electrolyte Imbalance
Contact your provider if you experience decreased urination, dark urine, persistent dizziness upon standing, rapid heartbeat, confusion, or muscle weakness. Severe gastrointestinal side effects causing significant fluid losses require medical assessment and possible treatment modification.
Indicators of Nutritional Deficiency
Persistent fatigue accompanied by pale skin, shortness of breath, cold intolerance, hair loss, or cognitive difficulties may suggest anemia or other nutritional deficiencies requiring laboratory investigation and supplementation.
Gallbladder Disease Symptoms
Seek prompt evaluation if you experience right upper abdominal pain, especially after eating, along with nausea, vomiting, fever, or yellowing of the skin or eyes. These may indicate gallbladder problems, which are a known risk with weight loss medications.
Thyroid-Related Concerns
Report symptoms such as neck swelling, hoarseness, or difficulty swallowing, which could relate to the boxed warning regarding thyroid C-cell tumors.
Vision Changes (for Patients with Diabetes)
Patients with diabetes should promptly report any vision changes, as diabetic retinopathy may worsen with rapid improvement in glucose control.
Routine Monitoring
Even without alarming symptoms, discuss fatigue at your regular follow-up appointments. Your healthcare provider can order appropriate laboratory tests including complete blood count, comprehensive metabolic panel, thyroid function tests, and vitamin levels to identify treatable causes. They can also assess whether medication adjustment, temporary discontinuation, or switching to an alternative weight loss approach would be appropriate for your individual situation. The American Diabetes Association recommends regular monitoring of patients on these medications to optimize safety and efficacy.
In clinical trials, fatigue occurred in 11.4% of Wegovy (semaglutide) users versus 5.2% on placebo, and in 7.2-10.8% of Zepbound (tirzepatide) users versus 4.1% on placebo. Individual experiences vary, with some patients reporting no energy changes while others experience significant tiredness.
Fatigue may result from multiple factors including significant caloric deficit from appetite suppression, metabolic adaptation to weight loss, nutritional deficiencies, gastrointestinal side effects affecting food and fluid intake, and changes in blood glucose levels. Dehydration and disrupted sleep from nausea can also contribute to tiredness.
Contact your healthcare provider if fatigue severely interferes with daily activities, progressively worsens, or occurs with symptoms like shakiness and confusion (suggesting hypoglycemia), right upper abdominal pain (possible gallbladder disease), persistent dizziness, or signs of nutritional deficiency such as pale skin and shortness of breath.
All medical content on this blog is created using reputable, evidence-based sources and is regularly reviewed for accuracy and relevance. While we strive to keep our content current with the latest research and clinical guidelines, it is intended for general informational purposes only.
This content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider with any medical questions or concerns. Use of this information is at your own risk, and we are not liable for any outcomes resulting from its use.
